Self-regulation of autologous cell therapies

Tuch, Bernard E; Wall, Dominic M

doi:10.5694/mja13.11043

Topics

Health services administration

A first step for a virtually unregulated industry

1 NSW Stem Cell Network, Sydney, NSW.
2 Centre for Genetic Diseases, Monash Institute of Medical Research, Monash University, Melbourne, VIC.
3 Australia and New Zealand Region, International Society for Cellular Therapy, Melbourne, VIC.
4 Department Pathology, University of Melbourne, Melbourne, VIC.

Correspondence: b.tuch@stemcellnetwork.org.au

Acknowledgements:

We thank Insoo Hyun for critical reading of the manuscript, Deborah Monk for advice about the code of conduct of Medicines Australia, and Heather Main for input into the steering committee and its operation.

Competing interests:

Bernard Tuch is a non-executive director of Living Cell Technologies Ltd, which is conducting clinical trials with xenografted cell therapies. He has received speaker and chairman fees from Abbott Laboratories and Merck Sharp and Dohme. Dominic Wall holds an unpaid management position for Cell Therapies Pty Ltd.

1. Macquarie Stem Cells. Candidacy. www.macquariestemcells.com/suitable-stem-cell-candidates (accessed Jan 2014).
2. Guilak F, Estes BT, Diekman BO, et al. Nicolas Andry Award: multipotent adult stem cells from adipose tissue for musculoskeletal tissue engineering. Clin Orthop Relat Res 2010; 468: 2530-2540.
3. Harmon K, Drezner J, Rao A. Platelet rich plasma for chronic tendinopathy [abstract]. Br J Sports Med 2013; 47: e2.
4. NSW Stem Cell Network. 17th NSW Stem Cell Network Workshop: cellular therapies for repair of musculoskeletal injuries. www.stemcellnetwork.org.au/past_events/workshops/17thWorkBookfinal.pdf (accessed Jan 2014).
5. Lochouarn M. France launches new drug regulatory agency. Lancet 2012; 379: 2136.

Online responses are no longer available. Please refer to our instructions for authors page for more information.